Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Portfolio Pulse from Jelena Martinovic
MediPharm Labs Corp. has entered into a licensing agreement with Remidose Aerosols Inc. to acquire exclusive rights for advanced cannabis products, including metered dose inhalers and pressurized sublingual sprays. MediPharm will service Remidose customers starting August 2024 and aims to expand its customer base using its existing GMP infrastructure.
June 20, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediPharm Labs Corp. has secured exclusive rights for advanced cannabis products through a licensing agreement with Remidose Aerosols Inc. This deal will allow MediPharm to service Remidose customers starting August 2024 and expand its customer base using its existing GMP infrastructure.
The licensing agreement with Remidose Aerosols Inc. provides MediPharm with exclusive rights to advanced cannabis products, which is likely to boost its revenue and expand its market reach. The company's existing GMP infrastructure will facilitate the integration of these new products without significant additional costs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100